Dylan Kotliar, Siddharth Raju, Shervin Tabrizi, Ikponmwosa Odia, Augustine Goba, Mambu Momoh, John Demby Sandi, Parvathy Nair, Eric Phelan, Ridhi Tariyal, Philomena E Eromon, Samar Mehta, Refugio Robles-Sikisaka, Katherine J Siddle, Matt Stremlau, Simbirie Jalloh, Stephen K Gire, Sarah Winnicki, Bridget Chak, Stephen F Schaffner, Matthias Pauthner, Elinor K Karlsson, Sarah R Chapin, Sharon G Kennedy, Luis M Branco, Lansana Kanneh, Joseph J Vitti, Nisha Broodie, Adrianne Gladden-Young, Omowunmi Omoniwa, Pan-Pan Jiang, Nathan Yozwiak, Shannon Heuklom, Lina M Moses, George O Akpede, Danny A Asogun, Kathleen Rubins, Susan Kales, Anise N Happi, Christopher O Iruolagbe, Mercy Dic-Ijiewere, Kelly Iraoyah, Omoregie O Osazuwa, Alexander K Okonkwo, Stefan Kunz, Joseph B McCormick, S Humarr Khan, Anna N Honko, Eric S Lander, Michael B A Oldstone, Lisa Hensley, Onikepe A Folarin, Sylvanus A Okogbenin, Stephan Günther, Hanna M Ollila, Ryan Tewhey, Peter O Okokhere, John S Schieffelin, Kristian G Andersen, Steven K Reilly, Donald S Grant, Robert F Garry, Kayla G Barnes, Christian T Happi, Pardis C Sabeti
Infection with Lassa virus (LASV) can cause Lassa fever, a haemorrhagic illness with an estimated fatality rate of 29.7%, but causes no or mild symptoms in many individuals. Here, to investigate whether human genetic variation underlies the heterogeneity of LASV infection, we carried out genome-wide association studies (GWAS) as well as seroprevalence surveys, human leukocyte antigen typing and high-throughput variant functional characterization assays. We analysed Lassa fever susceptibility and fatal outcomes in 533 cases of Lassa fever and 1,986 population controls recruited over a 7 year period in Nigeria and Sierra Leone...
February 7, 2024: Nature Microbiology